Sustained topical drug levels for innate immune agents

摘要

The present invention relates to a water-insoluble controlled release pattern recognition receptor agonist (“PRRA”) or a pharmaceutically acceptable salt thereof, or the water-insoluble controlled release PRRA or a pharmaceutically acceptable salt thereof, for use in the treatment of a cell proliferative disorder. A pharmaceutical composition comprising a possible salt, wherein the water-insoluble controlled release PRRA, a pharmaceutically acceptable salt or pharmaceutical composition thereof is administered by intratissue administration, wherein at least 25% of the amount of PRRA is administered 3 days after administration. a water-insoluble controlled-release PRRA, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that remains locally in such tissue even after; and related aspects.